Key result
Elevated NT-proBNP linked to ~3-fold higher odds of AF detection in ESUS or cryptogenic stroke.
Why the study?
Undiagnosed AF is a major risk factor for stroke in patients with ESUS or CS, but whether blood biomarkers of myocardial stress can accurately predict AF to guide monitoring was unclear.
Do elevated serum myocardial stress biomarkers predict atrial fibrillation development in patients with embolic stroke of undetermined source or cryptogenic stroke?
Meta-Analysis (n=6,212)
Do elevated serum myocardial stress biomarkers predict atrial fibrillation development in patients with embolic stroke of undetermined source or cryptogenic stroke?
Lower NT-proBNP levels have a high negative predictive value (91.7%) for ruling out atrial fibrillation in patients with ESUS/CS, potentially identifying those who do not require extended cardiac monitoring.
May guide extended AF monitoring decisions in ESUS/CS; extends biomarker association evidence from 9 studies.
BACKGROUND AND PURPOSE: Undiagnosed atrial fibrillation (AF) is a major risk factor for stroke that can go unnoticed in individuals with embolic stroke of undetermined source (ESUS) or cryptogenic stroke (CS). Early detection is critical for stroke prognosis and secondary prevention. This study aimed to determine if blood biomarkers of myocardial stress can accurately predict AF in patients with ESUS/CS, which would allow the identification of those who would benefit from closer monitoring. METHODS: In February 2023 we performed a systematic date-unrestricted search of three databases for studies on patients with ESUS/CS who were subsequently diagnosed with AF. We examined the relationships between AF and serum myocardial stress markers such as brain natriuretic peptide (BNP), N-terminal-pro-BNP (NT-proBNP), midregional proatrial natriuretic peptide, and troponin. RESULTS: Among the 1,527 studies reviewed, 23 eligible studies involving 6,212 participants, including 864 with AF, were analyzed. A meta-analysis of 9 studies indicated that they demonstrated a clear association between higher NT-proBNP levels and an increased risk of AF, with adjusted and raw data indicating 3.06- and 9.03-fold higher AF risks, respectively. Lower NT-proBNP levels had a pooled negative predictive value of 91.7%, indicating the potential to rule out AF with an 8% false-negative rate. CONCLUSIONS: Further research is required to fully determine the potential of biomarkers for AF detection after stroke, as results from previous studies lack homogeneity. However, lower NT-proBNP levels have potential in ruling out AF in patients with ESUS/CS. Combining them with other relevant biomarkers may enhance the precision of identifying patients who will not benefit from extended monitoring, which would optimize resource allocation and patient care.
No takes yet. Share an insight, caveat, or question.
Justo et al. (2024) conducted a meta-analysis in Embolic stroke of undetermined source (ESUS) or cryptogenic stroke (CS) (n=6,212). Elevated NT-proBNP levels vs. Lower NT-proBNP levels was evaluated on Atrial fibrillation detection (OR 3.06, 95% CI 1.66-5.63). Elevated NT-proBNP levels were associated with a 3.06-fold increased odds of atrial fibrillation detection in patients with embolic stroke of undetermined source or cryptogenic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: